|
**Overview**: Urine Drugs Panel-6**Introduction**: The Urine Drugs Panel-6 is a diagnostic tool designed for substance abuse screening using urine samples. In India, expanded drug panels (amphetamines, barbiturates, cannabinoids, cocaine, opiates, phencyclidine) cover common abused substances in youth, workplaces, and medico-legal cases. High morbidity from under-testing leading to undetected impairment or delayed rehabilitation. Per forensic/toxicology practices aligned with ICMR and Narcotics Control Bureau guidelines, the test employs chromatography/mass spectrometry for 6 drugs over 1â€"2 days with high accuracy, valuable for broader screening than 5-panel. This diagnostic falls under drug screening and targets pre-employment, post-accident, or suspected abuse cases, addressing accurate detection to guide counseling or legal measures. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling reliable multi-drug profiling and reducing substance-related harm. Its urine-based approach ensures reliable multi-drug detection.**Other Names**: Urine 6 Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/clinical pathology, compliant with 2025 standards.**Historical Milestone**: 6-panel urine drug screen standard in many sectors; in India, common in corporate testing.**Purpose**: The test assesses 6 parameters including amphetamines to guide substance abuse screening, detect recent use, inform intervention.**Test Parameters**: 1. Amphetamines, 2. Barbiturates, 3. Cannabinoids, 4. Cocaine, 5. Opiates, 6. Phencyclidine.**Pretest Condition**: No fasting required; patients should provide urine sample.**Specimen**: 10 mL urine in sterile container, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 2 hours with proper handling to preserve drug metabolites, ensuring reliable test performance.**Sample Stability at Refrigeration**: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not frozen (fresh sample preferred for chromatography).**Medical History**: Patients should provide details on medication, substance use.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected abuse including health/legal issues, benefits of screening, and minimal discomfort from urine collection.**Procedural Considerations**: The test involves sample processing using chromatography/mass spectrometry by trained personnel to ensure chain-of-custody and interpret results within 1â€"2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, adulteration can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive result confirms recent use, necessitating specialist input.**Specialist Consultation**: Toxicologists or psychiatrists should be consulted for management.**Additional Supporting Tests**: Confirmatory GC-MS for positives.**Test Limitations**: Detection windows vary; comprehensive approach required.**References**: Indian Journal of Pharmacology 2024, Toxicology Studies India 2023. |
